<DOC>
	<DOCNO>NCT02859441</DOCNO>
	<brief_summary>Objective : Von Hippel-Lindau ( VHL ) disease autosomal dominant heritable disorder multiple benign malignant neoplasms cyst specific histopathologies develop kidney , adrenal gland , pancreas , brain , spinal cord , eye , inner ear , epididymis broad ligament . The disease affect 7,000 individual United States . Retinal capillary hemangioma ( RCH ) common often early manifestation VHL disease may lead significant vision loss . In eye , inexorable progression RCH lead blindness phthisis bulbi despite aggressive treatment . Levels vascular endothelial growth factor ( VEGF ) , potent mediator angiogenesis vascular permeability , show elevated multiple cell type deficient VHL protein ( pVHL ) . Platelet-derived growth factor ( PDGF ) , important role stabilization immature new vessel angiogenesis , upregulated pVHL-defective cell line express pVHL-defective tumor . Anti-VEGF therapy alone beneficial effect ocular VHL disease two previous phase 1 study . The objective study investigate safety possible efficacy combination investigational treatment serial intravitreal injection E10030 , PDGF-B antagonist , ranibizumab , VEGF-A antagonist , participant severe ocular VHL disease . Study Population : Five participant severe ocular VHL disease receive combination investigational treatment one eye follow 104 week . Up additional two participant may enrol replace participant withdraw study prior Week 52 visit . Design : In phase I/II , single-center , prospective , open label , non-randomized , uncontrolled , single group trial , one eye eligible participant treat investigational product , E10030 , PDGF-B antagonist , ranibizumab , VEGF-A antagonist . Participants receive combination investigational treatment consist intravitreal injection E10030 ( 1.5 mg 0.05 mL ) ranibizumab ( 0.5 mg 0.05 mL ) every four week baseline Week 16 ( total five treatment ) every eight week Week 48 ( total nine treatment baseline ) . Starting Week 52 , participant meet criterion sufficient response eligible continue receive injection need frequently every 4 week Week 92 treatment extension phase . All participant follow 104 week . Outcome Measures : The primary outcome study safety combination investigational treatment , assess tabulation adverse event report Week 52 . Secondary outcome include tabulation adverse event Week 104 , follow measure study eye Week 52 104 : proportion participant experience reduction size least one RCH absence ablative treatment ( assessed fundus photography fluorescein angiography [ FA ] ) ; proportion participant experience moderate vision loss ( defined loss great equal 15 letter baseline Electronic Visual Acuity [ EVA ] test ) ; mean change visual acuity ; change size RCH ( measure fundus photography FA ) ; change exudation ( measure fundus photography , optical coherence tomography [ OCT ] FA ) ; change epiretinal proliferation , fibrosis retinal traction ( assessed OCT fundus photography ) ; proportion participant undergo ablative treatment RCH ocular surgery ; proportion participant successful ablative treatment RCH ; proportion participant appearance one new RCH .</brief_summary>
	<brief_title>A Phase I/II Trial Intravitreous Treatment Severe Ocular Von Hippel-Lindau Disease Using Combination PDGF Antagonist E10030 VEGF Antagonist Ranibizumab</brief_title>
	<detailed_description>Objective : Von Hippel-Lindau ( VHL ) disease autosomal dominant heritable disorder multiple benign malignant neoplasms cyst specific histopathologies develop kidney , adrenal gland , pancreas , brain , spinal cord , eye , inner ear , epididymis broad ligament . The disease affect 7,000 individual United States . Retinal capillary hemangioma ( RCH ) common often early manifestation VHL disease may lead significant vision loss . In eye , inexorable progression RCH lead blindness phthisis bulbi despite aggressive treatment . Levels vascular endothelial growth factor ( VEGF ) , potent mediator angiogenesis vascular permeability , show elevated multiple cell type deficient VHL protein ( pVHL ) . Platelet-derived growth factor ( PDGF ) , important role stabilization immature new vessel angiogenesis , upregulated pVHL-defective cell line express pVHL-defective tumor . Anti-VEGF therapy alone beneficial effect ocular VHL disease two previous phase 1 study . The objective study investigate safety possible efficacy combination investigational treatment serial intravitreal injection E10030 , PDGF-B antagonist , ranibizumab , VEGF-A antagonist , participant severe ocular VHL disease . Study Population : Five participant severe ocular VHL disease receive combination investigational treatment one eye follow 104 week . Up additional two participant may enrol replace participant withdraw study prior Week 52 visit . Design : In phase I/II , single-center , prospective , open label , non-randomized , uncontrolled , single group trial , one eye eligible participant treat investigational product , E10030 , PDGF-B antagonist , ranibizumab , VEGF-A antagonist . Participants receive combination investigational treatment consist intravitreal injection E10030 ( 1.5 mg 0.05 mL ) ranibizumab ( 0.5 mg 0.05 mL ) every four week baseline Week 16 ( total five treatment ) every eight week Week 48 ( total nine treatment baseline ) . Starting Week 52 , participant meet criterion sufficient response eligible continue receive injection need frequently every 4 week Week 92 treatment extension phase . All participant follow 104 week . Outcome Measures : The primary outcome study safety combination investigational treatment , assess tabulation adverse event report Week 52 . Secondary outcome include tabulation adverse event Week 104 , follow measure study eye Week 52 104 : proportion participant experience reduction size least one RCH absence ablative treatment ( assessed fundus photography fluorescein angiography [ FA ] ) ; proportion participant experience moderate vision loss ( defined loss great equal 15 letter baseline Electronic Visual Acuity [ EVA ] test ) ; mean change visual acuity ; change size RCH ( measure fundus photography FA ) ; change exudation ( measure fundus photography , optical coherence tomography [ OCT ] FA ) ; change epiretinal proliferation , fibrosis retinal traction ( assessed OCT fundus photography ) ; proportion participant undergo ablative treatment RCH ocular surgery ; proportion participant successful ablative treatment RCH ; proportion participant appearance one new RCH .</detailed_description>
	<mesh_term>Von Hippel-Lindau Disease</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Participant Eligibility Criteria The participant must meet eligibility criterion none exclusion criterion . INCLUSION CRITERIA : 1 . Participant must understand sign inform consent . 2 . Participant must 18 year age old . 3 . Participant must diagnosis VHL disease . In accordance establish criterion diagnosis , one following consider sufficient evidence VHL disease present : A family history VHL disease plus one follow lesion : RCH , spinal cerebellar hemangioblastoma , pheochromocytoma , multiple pancreatic cyst , epididymal broad ligament cystadenomas , multiple renal cyst renal cell carcinoma age 60 year . Presence two hemangioblastomas retina brain single hemangioblastoma association visceral manifestation kidney pancreatic cyst ; renal cell carcinoma ; adrenal extraadrenal pheochromocytoma ; endolymphatic sac tumor ; papillary cystadenomas epididymis broad ligament ; neuroendocrine tumor pancreas . Presence known diseasecausing germline mutation VHL gene . 4 . Any female participant childbearing potential ( see Appendix 1 definition ) must pregnant breastfeeding , must negative pregnancy test screening must willing undergo pregnancy test immediately prior treatment . 5 . Any female participant childbearing potential ( see Appendix 1 definition ) male participant able father child must ( partner ) hysterectomy vasectomy , completely abstinent intercourse must agree practice two effective method contraception throughout course study least two month follow last administration combination investigational treatment . Acceptable method contraception include : hormonal contraception ( i.e. , birth control pill , inject hormone , dermal patch vaginal ring ) , intrauterine device , barrier method ( diaphragm condom ) spermicide , surgical sterilization ( hysterectomy , tubal ligation vasectomy ) . EXCLUSION CRITERIA : 1 . Participant history evidence significant cardiac disease ( example , use cardiac medication aside agent control blood pressure , past acute coronary syndrome , past myocardial infarction , past revascularization procedure arrhythmia require past present treatment ) . 2 . Participant history stroke transient ischemic attack . Note : cerebrovascular manifestation and/or complication central nervous system hemangioblastomas exclusionary , absence past stroke transient ischemic attack . 3 . Participant use systemic medication significant antiVEGF antiPDGF activity within 30 day study entry expect use medication within 12 month study entry . 4 . Participant medically unable comply study procedure follow judgment investigator . 5 . Participant diagnosis diabetic mellitus ( type 1 type 2 ) . Any one following consider sufficient evidence diabetes present : Current regular use insulin treatment diabetes , Current regular use oral antihyperglycemia agent treatment diabetes , Hemoglobin A1C great equal 6.5 % , Documented diabetes ADA and/or WHO criteria . Study Eye Eligibility Criteria The participant must least one eye meeting inclusion criterion none exclusion criterion list . INCLUSION CRITERIA : 1 . Participant least one RCH secondary VHL disease study eye fulfills follow criterion : 1 . The RCH must exhibit growth potential consequent threat vision . Growth potential consequent threat vision define AT LEAST ONE following : Associated intra subretinal exudation lipid deposition , judgment investigator , reflect ongoing vascular incompetence solely reflective residual change follow previous treatment solely secondary coexistent retinal traction . Increased size tumor compare previous time point assess fundus photography FA . Associated intra , sub preretinal hemorrhage secondary previous treatment , assess fundus photography FA . The presence dilate and/or tortuous feeder vessel . Vitreous cell haze indicative vitreous exudation , absence ocular feature potentially responsible finding . 2 . The RCH , judgment investigator , NOT readily treatable use thermal laser size , posterior location , poor previous response conventional therapy , association significant exudation , epiretinal proliferation , associate vascular abnormality vascular proliferation diffusely incompetent retinal vessel , factor predictive poor response standard care approach . 2 . The study eye must clarity ocular medium degree pupil dilation sufficient permit adequate fundus photography . EXCLUSION CRITERIA : 1 . The study eye present chronic ocular periocular infection ( include history ocular herpes zoster ) . 2 . The study eye chronic glaucoma ; OR receive antiglaucoma medication time within 90 day study entry ; OR significant ocular hypertension , define document intraocular pressure great equal 28 mmHg occasion absence selflimited acute glaucoma , OR great equal 24 mmHg least two occasion absence selflimited acute glaucoma . Note : History selflimited acute glaucoma study eye , resolve expect recur , exclusionary . History glaucoma ocular hypertension fellow eye , felt significantly impact risk glaucoma study eye , exclusionary . 3 . The study eye undergone surgical procedure within 60 day prior study entry ( inclusive cryotherapy thermal laser ) . 4 . The study eye history intravitreal injection antiVEGF agent ( bevacizumab , ranibizumab aflibercept ) within 42 day prior study entry . 5 . The study eye history intravitreal periocular injection longacting corticosteroid ( triamcinolone acetonide ) within 90 day study entry history sustainedrelease ocular drug delivery device reasonable expectation residual activity study eye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 22, 2017</verification_date>
	<keyword>Intravitreal Injection</keyword>
	<keyword>Retinal Capillary Hemangioma</keyword>
</DOC>